D. Boral Capital Reaffirms “Buy” Rating for Medicus Pharma (NASDAQ:MDCX)

Medicus Pharma (NASDAQ:MDCX)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $14.00 price target on the stock. D. Boral Capital’s price target would suggest a potential upside of 250.00% from the company’s current price.

Other equities research analysts have also issued reports about the company. Brookline Capital Management upgraded Medicus Pharma to a “strong-buy” rating in a research report on Monday, December 23rd. D Boral Capital upgraded Medicus Pharma to a “strong-buy” rating in a research note on Monday, April 14th.

Medicus Pharma Stock Performance

Shares of MDCX opened at $4.00 on Monday. Medicus Pharma has a 1 year low of $1.80 and a 1 year high of $6.00. The company has a fifty day moving average price of $3.54.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. Research analysts anticipate that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC bought a new stake in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma comprises 1.3% of Interchange Capital Partners LLC’s investment portfolio, making the stock its 15th largest holding. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma at the end of the most recent quarter.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.